Drug reference

Clodronate

Bisphosphonate · Bone Resorption Inhibitor

Also known as Sodium clodronate, Bonefos, Clasteon

BisphosphonateBone Resorption Inhibitor

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

Avoid.

FDA category + note

Mechanism

Clodronate, a bisphosphonate, has a strong affinity for bone surfaces undergoing remodeling. It directly inhibits osteoclast-mediated bone resorption, acting as a potent antiresorptive agent. This mechanism reduces excessive bone breakdown, which is clinically useful for treating osteolytic lesions, hypercalcaemia, and bone pain associated with skeletal metastases.

Indications

Paget diseasetreatment and prevention of osteoporosishypercalcemia of malignancyprevention of bone loss in breast cancer and multiple myeloma

Dosing

Adult: 1-2 tablets (520 mg/tablet) in divided doses, increased if necessary up to 4 tablets (2080 mg) daily.
Renal adjustment: Avoid if eGFR less than 10 mL/minute/1.73 m2. Max. initial dose 1200 mg daily if eGFR 30-50 mL/minute/1.73m2. Use half normal dose if eGFR 10–30 mL/minute/1.73 m2.
Max dose: 2080 mg daily (4 tablets of 520 mg)